1,117 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Sands Capital Management Buys Align Technology Inc, Ctrip. ... http://www.gurufocus.com/news/682879/sands-capital-management-buys-align-technology-inc-ctripcom-international-aptiv-plc-sells-biogen-inc-booking-holdings-inc-chipotle-mexican-grill-inc May 15, 2018 - Sands Capital Management Buys Align Technology Inc, Ctrip.com International, Aptiv PLC, Sells Biogen Inc, Booking Holdings Inc, Chipotle Mexican Grill Inc, Stocks: CTRP,AGN,VRSK,DG,INTU,ROST,ALGN,APTV,BIIB,CMG,IWF,, release date:May 15, 2018
Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO https://seekingalpha.com/article/4174191-kiniksa-pharmaceuticals-aims-126-million-u-s-ipo?source=feed_tag_ipo_analysis May 15, 2018 - Kiniksa Pharmaceuticals has filed to raise $126 million in an IPO of its Class A stock.The firm is developing a pipeline of anti-inflammatory disease treatments.KNSA has strong finances and excellent
Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update https://seekingalpha.com/article/4174148-tracking-seth-klarmans-baupost-group-holdings-q1-2018-update?source=feed_all_articles May 15, 2018 - Seth Klarman’s 13F portfolio value increased from $10.11B to $10.37B this quarter.Baupost Group doubled its stake in Pioneer Natural Resources during the quarter.The portfolio continues to be heavily
Teachers Advisors Inc Buys Xilinx Inc, Allergan PLC, iShares Russell 1000 Value, Sells Melco ... http://www.gurufocus.com/news/682270/teachers-advisors-inc-buys-xilinx-inc-allergan-plc-ishares-russell-1000-value-sells-melco-resorts-and-entertainment-union-pacific-corp-albemarle-corp May 14, 2018 - Teachers Advisors Inc Buys Xilinx Inc, Allergan PLC, iShares Russell 1000 Value, Sells Melco Resorts and Entertainment, Union Pacific Corp, Albemarle Corp, Stocks: XLNX,AGN,IWD,ABT,ZBH,FTI,WP,ZS,EHC,NTR,SYNH,VICI,U, release date:May 14, 2018
Evolus: Is The Botox Knock Off Finally Here? https://seekingalpha.com/article/4173864-evolus-botox-knock-finally?source=feed_sector_healthcare May 14, 2018 - EOLS spiked Monday ahead of an FDA decision pursuant to a PDUFA for its botulinum toxin DWP-450.The FDA issued a Form 483 with 10 observations after a pre-approval inspection of the plant producing th
Will Mullets Bail Out Allergan? https://seekingalpha.com/article/4173678-will-mullets-bail-allergan?source=feed_sector_healthcare May 14, 2018 - AGN is seeking strategic options to boost shareholder value.It may try to sell parts of AGN before LOE for Restasis or competition for Botox materializes.If investors buy this new narrative it could r
Your Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, President's Healthcare Plans https://seekingalpha.com/article/4173620-daily-pharma-scoop-omeros-update-synergy-sales-presidents-healthcare-plans?source=feed_sector_healthcare May 14, 2018 - Omeros, which we are strongly bullish on, is up 23% on good news from OMS721. Synergy is down on poor Trulance numbers. President Trump unveils his relatively non-invasive plans for drug pricing.
Johnson & Johnson: Waiting On The Wave https://seekingalpha.com/article/4173014-johnson-and-johnson-waiting-wave?source=feed_sector_healthcare May 11, 2018 - Last August, the Financial Times warned of a tidal wave of lawsuits related to the opioids crisis was heading for JNJ and its competitors.That doesn't appear to have come up on JNJ's Q1 conference cal
Allergan: Could The Break-Up Be The Solution? https://seekingalpha.com/article/4172906-allergan-break-solution?source=feed_sector_healthcare May 11, 2018 - Aesthetics franchise is a key franchise for Allergan.I have run few DCF analyses to show what is a potential valuation of Allergan's aesthetics franchise.The outcome of my analysis is that this busine
Synergy's Q1 Earnings: Slow Growth, Worrying Financials, And The Prospect Of Partnerships https://seekingalpha.com/article/4172801-synergys-q1-earnings-slow-growth-worrying-financials-prospect-partnerships?source=feed_sector_healthcare May 11, 2018 - Synergy reported earnings for Q1 2018 on May 10.The company reported a lower-than-expected net loss, but missed on revenues, thanks to slow growth in sales of constipation drug Trulance; shares took a

Pages: 12345678...112

<<<Page 3>